Intranasal leptin relieves sleep-disordered breathing in mice with diet-induced obesity

Slava Berger, Huy Pho, Thomaz Fleury Curado, Shannon Bevans-Fonti, Haris Younas, Mi-Kyung Shin, Jonathan Jun, Frederick Anokye-Danso, Rexford S Ahima, Lynn W. Enquist, David Mendelowitz, Alan R. Schwartz, Vsevolod Polotsky

Research output: Contribution to journalArticle

Abstract

Rationale: Leptin treats upper airway obstruction and alveolar hypoventilation in leptin-deficient ob/ob mice. However, obese humans and mice with diet-induced obesity (DIO) are resistant to leptin because of poor permeability of the blood–brain barrier. We propose that intranasal leptin will bypass leptin resistance and treat sleep-disordered breathing in obesity. Objectives: To assess if intranasal leptin can treat obesity hypoventilation and upper airway obstruction during sleep in mice with DIO. Methods: Male C57BL/6J mice were fed with a high-fat diet for 16 weeks. A single dose of leptin (0.4 mg/kg) or BSA (vehicle) were administered intranasally or intraperitoneally, followed by either sleep studies (n = 10) or energy expenditure measurements (n = 10). A subset of mice was treated with leptin daily for 14 days for metabolic outcomes (n = 20). In a separate experiment, retrograde viral tracers were used to examine connections between leptin receptors and respiratory motoneurons. Measurements and Main Results: Acute intranasal, but not intraperitoneal, leptin decreased the number of oxygen desaturation events in REM sleep, and increased ventilation in non-REM and REM sleep, independently of metabolic effects. Chronic intranasal leptin decreased food intake and body weight, whereas intraperitoneal leptin had no effect. Intranasal leptin induced signal transducer and activator of transcription 3 phosphorylation in hypothalamic and medullary centers, whereas intraperitoneal leptin had no effect. Leptin receptor–positive cells were synaptically connected to respiratory motoneurons. Conclusions: In mice with DIO, intranasal leptin bypassed leptin resistance and significantly attenuated sleep-disordered breathing independently of body weight.

Original languageEnglish (US)
Pages (from-to)773-783
Number of pages11
JournalAmerican journal of respiratory and critical care medicine
Volume199
Issue number6
DOIs
StatePublished - Mar 15 2019

Fingerprint

Sleep Apnea Syndromes
Leptin
Obesity
Diet
Hypoventilation
REM Sleep
Motor Neurons
Airway Obstruction
Sleep
Body Weight
Leptin Receptors
STAT3 Transcription Factor
Obese Mice
High Fat Diet
Inbred C57BL Mouse
Energy Metabolism
Ventilation

Keywords

  • Hypoventilation
  • Leptin
  • Respiration
  • Sleep apnea syndromes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Intranasal leptin relieves sleep-disordered breathing in mice with diet-induced obesity. / Berger, Slava; Pho, Huy; Fleury Curado, Thomaz; Bevans-Fonti, Shannon; Younas, Haris; Shin, Mi-Kyung; Jun, Jonathan; Anokye-Danso, Frederick; Ahima, Rexford S; Enquist, Lynn W.; Mendelowitz, David; Schwartz, Alan R.; Polotsky, Vsevolod.

In: American journal of respiratory and critical care medicine, Vol. 199, No. 6, 15.03.2019, p. 773-783.

Research output: Contribution to journalArticle

@article{772b850b671146e685d30c434a9bcbcf,
title = "Intranasal leptin relieves sleep-disordered breathing in mice with diet-induced obesity",
abstract = "Rationale: Leptin treats upper airway obstruction and alveolar hypoventilation in leptin-deficient ob/ob mice. However, obese humans and mice with diet-induced obesity (DIO) are resistant to leptin because of poor permeability of the blood–brain barrier. We propose that intranasal leptin will bypass leptin resistance and treat sleep-disordered breathing in obesity. Objectives: To assess if intranasal leptin can treat obesity hypoventilation and upper airway obstruction during sleep in mice with DIO. Methods: Male C57BL/6J mice were fed with a high-fat diet for 16 weeks. A single dose of leptin (0.4 mg/kg) or BSA (vehicle) were administered intranasally or intraperitoneally, followed by either sleep studies (n = 10) or energy expenditure measurements (n = 10). A subset of mice was treated with leptin daily for 14 days for metabolic outcomes (n = 20). In a separate experiment, retrograde viral tracers were used to examine connections between leptin receptors and respiratory motoneurons. Measurements and Main Results: Acute intranasal, but not intraperitoneal, leptin decreased the number of oxygen desaturation events in REM sleep, and increased ventilation in non-REM and REM sleep, independently of metabolic effects. Chronic intranasal leptin decreased food intake and body weight, whereas intraperitoneal leptin had no effect. Intranasal leptin induced signal transducer and activator of transcription 3 phosphorylation in hypothalamic and medullary centers, whereas intraperitoneal leptin had no effect. Leptin receptor–positive cells were synaptically connected to respiratory motoneurons. Conclusions: In mice with DIO, intranasal leptin bypassed leptin resistance and significantly attenuated sleep-disordered breathing independently of body weight.",
keywords = "Hypoventilation, Leptin, Respiration, Sleep apnea syndromes",
author = "Slava Berger and Huy Pho and {Fleury Curado}, Thomaz and Shannon Bevans-Fonti and Haris Younas and Mi-Kyung Shin and Jonathan Jun and Frederick Anokye-Danso and Ahima, {Rexford S} and Enquist, {Lynn W.} and David Mendelowitz and Schwartz, {Alan R.} and Vsevolod Polotsky",
year = "2019",
month = "3",
day = "15",
doi = "10.1164/rccm.201805-0879OC",
language = "English (US)",
volume = "199",
pages = "773--783",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Intranasal leptin relieves sleep-disordered breathing in mice with diet-induced obesity

AU - Berger, Slava

AU - Pho, Huy

AU - Fleury Curado, Thomaz

AU - Bevans-Fonti, Shannon

AU - Younas, Haris

AU - Shin, Mi-Kyung

AU - Jun, Jonathan

AU - Anokye-Danso, Frederick

AU - Ahima, Rexford S

AU - Enquist, Lynn W.

AU - Mendelowitz, David

AU - Schwartz, Alan R.

AU - Polotsky, Vsevolod

PY - 2019/3/15

Y1 - 2019/3/15

N2 - Rationale: Leptin treats upper airway obstruction and alveolar hypoventilation in leptin-deficient ob/ob mice. However, obese humans and mice with diet-induced obesity (DIO) are resistant to leptin because of poor permeability of the blood–brain barrier. We propose that intranasal leptin will bypass leptin resistance and treat sleep-disordered breathing in obesity. Objectives: To assess if intranasal leptin can treat obesity hypoventilation and upper airway obstruction during sleep in mice with DIO. Methods: Male C57BL/6J mice were fed with a high-fat diet for 16 weeks. A single dose of leptin (0.4 mg/kg) or BSA (vehicle) were administered intranasally or intraperitoneally, followed by either sleep studies (n = 10) or energy expenditure measurements (n = 10). A subset of mice was treated with leptin daily for 14 days for metabolic outcomes (n = 20). In a separate experiment, retrograde viral tracers were used to examine connections between leptin receptors and respiratory motoneurons. Measurements and Main Results: Acute intranasal, but not intraperitoneal, leptin decreased the number of oxygen desaturation events in REM sleep, and increased ventilation in non-REM and REM sleep, independently of metabolic effects. Chronic intranasal leptin decreased food intake and body weight, whereas intraperitoneal leptin had no effect. Intranasal leptin induced signal transducer and activator of transcription 3 phosphorylation in hypothalamic and medullary centers, whereas intraperitoneal leptin had no effect. Leptin receptor–positive cells were synaptically connected to respiratory motoneurons. Conclusions: In mice with DIO, intranasal leptin bypassed leptin resistance and significantly attenuated sleep-disordered breathing independently of body weight.

AB - Rationale: Leptin treats upper airway obstruction and alveolar hypoventilation in leptin-deficient ob/ob mice. However, obese humans and mice with diet-induced obesity (DIO) are resistant to leptin because of poor permeability of the blood–brain barrier. We propose that intranasal leptin will bypass leptin resistance and treat sleep-disordered breathing in obesity. Objectives: To assess if intranasal leptin can treat obesity hypoventilation and upper airway obstruction during sleep in mice with DIO. Methods: Male C57BL/6J mice were fed with a high-fat diet for 16 weeks. A single dose of leptin (0.4 mg/kg) or BSA (vehicle) were administered intranasally or intraperitoneally, followed by either sleep studies (n = 10) or energy expenditure measurements (n = 10). A subset of mice was treated with leptin daily for 14 days for metabolic outcomes (n = 20). In a separate experiment, retrograde viral tracers were used to examine connections between leptin receptors and respiratory motoneurons. Measurements and Main Results: Acute intranasal, but not intraperitoneal, leptin decreased the number of oxygen desaturation events in REM sleep, and increased ventilation in non-REM and REM sleep, independently of metabolic effects. Chronic intranasal leptin decreased food intake and body weight, whereas intraperitoneal leptin had no effect. Intranasal leptin induced signal transducer and activator of transcription 3 phosphorylation in hypothalamic and medullary centers, whereas intraperitoneal leptin had no effect. Leptin receptor–positive cells were synaptically connected to respiratory motoneurons. Conclusions: In mice with DIO, intranasal leptin bypassed leptin resistance and significantly attenuated sleep-disordered breathing independently of body weight.

KW - Hypoventilation

KW - Leptin

KW - Respiration

KW - Sleep apnea syndromes

UR - http://www.scopus.com/inward/record.url?scp=85062948055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062948055&partnerID=8YFLogxK

U2 - 10.1164/rccm.201805-0879OC

DO - 10.1164/rccm.201805-0879OC

M3 - Article

C2 - 30309268

AN - SCOPUS:85062948055

VL - 199

SP - 773

EP - 783

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -